USC-Brookings Schaeffer on Health Policy
Other featured articles
Tweaking the Marketplace Enrollment Process Could Magnify Effects of Larger Premium Tax Credits
The Inflation Reduction Act included a three-year extension of enhancements to the premium tax credit that were originally enacted in 2021.Posted in
Comments on the Request for Information on Medicare
Schaeffer Initiative experts submitted a comment letter responding to a recent request for information (RFI) related to the Medicare Advantage (MA) program
To Prevent Public Health Crises, We Need to Update the Essential Medical Product List
USC-Brookings Schaeffer Initiate for Health Policy experts rights that policymakers should create a list of critically important products to avoid supply chain shortages.Posted in
Tackling Unfinished Business and Taking on Current Challenges: Putting Biden’s Mental Health Proposals in Context
An analysis of the Biden administrations plan to address mental health.Posted in
About this section
On this blog, experts from the USC-Brookings Schaeffer Initiative for Health Policy advance the national health policy conversation through innovative ideas and timely, evidence-based analysis. These posts offer policymakers practical recommendations and analysis for solving the health care issues of today.
More from USC-Brookings Schaeffer on Health Policy Blog
What Does Economy-Wide Inflation Mean for the Prices of Healthcare Services (and Vice Versa)?
While consumer prices rose more than 6% over the 12-month period ending in January 2022, Matthew Fiedler writes that healthcare services have been an exception with only modest increases above pre-pandemic rates.
Comments On the 2023 Advance Notice On Medicare Part C and D Payment Policies
Matthew Fiedler and Richard Frank commented on the 2023 Medicare Part C and D Advance Notice issued by the Centers for Medicare and Medicaid Services (CMS).
The Debate on Overpayment In Medicare Advantage: Pulling It together
Health Affairs Forefront has published articles that advance two diametrically opposing assessments of issues regarding the Medicare Advantage program. Ginsburg and Lieberman discuss them and why it is important to come to agreement.
New Evidence Suggests a Lack of Cost-Shifting in Prescription Drug Markets
Recent legislative efforts to regulate drug prices have reignited debates about the interaction between price setting in public insurance programs and commercial market spending.
Comments on the 2023 Notice of Benefit and Payment Parameters
Loren Adler, Erin Duffy, and Matthew Fiedler recently provided comments to the Centers for Medicare and Medicaid Services (CMS) on CMS’ proposal to resume network adequacy reviews for qualified health plans offered in states that use the federal enrollment platform.